Henry Schein (NASDAQ:HSIC) CEO Stanley Bergman Sells 38,346 Shares

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 38,346 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $81.01, for a total value of $3,106,409.46. Following the sale, the chief executive officer owned 427,615 shares in the company, valued at approximately $34,641,091.15. This represents a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Henry Schein Trading Up 1.1%

Shares of Henry Schein stock opened at $82.39 on Friday. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $89.29. The firm has a market capitalization of $9.45 billion, a PE ratio of 25.20, a price-to-earnings-growth ratio of 2.41 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.79. The company’s fifty day moving average price is $77.85 and its two-hundred day moving average price is $72.15.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same period in the previous year, the business earned $1.19 EPS. The firm’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on HSIC. Morgan Stanley boosted their price target on shares of Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research report on Wednesday. Robert W. Baird set a $100.00 target price on shares of Henry Schein and gave the company an “outperform” rating in a research note on Monday. Evercore increased their price target on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Barclays assumed coverage on Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 price target for the company. Finally, Mizuho boosted their price objective on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Henry Schein presently has an average rating of “Hold” and a consensus target price of $85.58.

Hedge Funds Weigh In On Henry Schein

Several large investors have recently bought and sold shares of the business. Compound Planning Inc. acquired a new stake in Henry Schein during the 4th quarter worth $275,000. Corient Private Wealth LLC boosted its position in shares of Henry Schein by 5.4% in the 4th quarter. Corient Private Wealth LLC now owns 37,019 shares of the company’s stock worth $2,798,000 after purchasing an additional 1,906 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its stake in shares of Henry Schein by 7.8% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company’s stock worth $326,000 after purchasing an additional 312 shares during the period. State of Tennessee Department of Treasury increased its holdings in Henry Schein by 411.7% in the fourth quarter. State of Tennessee Department of Treasury now owns 75,773 shares of the company’s stock valued at $5,719,000 after purchasing an additional 60,965 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in Henry Schein by 202.4% during the fourth quarter. Mackenzie Financial Corp now owns 10,933 shares of the company’s stock worth $834,000 after buying an additional 7,318 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.